[Asia Economy Reporter Chunhee Lee] ABL Bio, a bispecific antibody specialist company ABL Bio, announced on the 30th that it will attend the 2022 American Society of Clinical Oncology (ASCO) and its subsidiary event, the McKinsey Symposium, held in Chicago, USA from the 3rd to the 7th of next month (local time) to discuss pipeline clinical development.
ASCO, considered one of the world's top three cancer conferences, is attended annually by numerous medical professionals, scientists, multinational pharmaceutical companies, and biotech firms to present the latest research achievements and clinical data on anticancer drugs.
At this year's ASCO, ABL Bio plans to grasp the current status of clinical development in the oncology field and continue close discussions with local researchers and partners regarding ongoing clinical trials. Additionally, on the opening day, the 3rd, it will participate in the 'ASCO McKinsey Symposium' hosted by the management consulting firm McKinsey as a subsidiary event.
This McKinsey Symposium is held under the theme ‘Asian Anticancer Drugs Preparing to Leap onto the Global Stage.’ Participants include Daiichi Sankyo from Japan, BeiGene and CStone Pharmaceuticals from China. Among domestic companies, CEO Sanghoon Lee of ABL Bio was the only panelist invited.
CEO Lee said, "I am pleased to be officially invited by McKinsey to participate as a panelist in a forum discussing anticancer drug development in the Asian region," adding, "This invitation confirms that ABL Bio's expertise in the field of immuno-oncology is recognized worldwide, and we will continue to accelerate clinical trials of our pipeline through ongoing research and development to become a leading global bio company in the immuno-oncology market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
